Search Results

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024.

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the first quarter of 2024.

PDS Biotechnology Corporation announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer, effective as of May 1, 2024.

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”),VERSATILE-002 is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a data update from its ongoing VERSATILE-002 Phase 2 clinical trial.

PDS Biotechnology Corporation announced that the Company will report financial results for the first quarter of 2024 and provide a business update on Wednesday, May 15, 2024, before the market opens.

PDS Biotechnology Corporation announced additional details of its virtual Key Opinion Leader event to be held on Wednesday, May 8, 2024 at 1:30 PM ET.

PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, announced that the Company will participate in two upcoming investor conferences taking place in May 2024.

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”) hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer (“HNSCC”) discussed positive, updated VERSATILE-002 data and the unmet need in HPV16-positive HNSCC.

Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.